GWP42004: Phase IIa data

A 5-arm, double-blind, placebo-controlled, exploratory Phase IIa trial in 62 Type II diabetics showed that twice-daily 5 mg GWP42004 led to no improvement on the primary endpoint of increasing HDL-C l...